The takeaway
Sanofi ADR shows a moderate seasonal pattern over 10 years of data — strongest in April (+2.6%) and softest in February (−2.3%).
Right now
In July, the stock has risen 40% of years, averaging 0.0%, roughly 2.1 pts behind the S&P 500.
The full picture
Sanofi ADR's most dependable month has been April, higher in 7 of 10 years; February has been its least reliable, up just 30% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in March (+1.6 pts); it has trailed the market most in October (−2.8 pts).
“vs S&P” is Sanofi ADR’s average for a month minus the S&P 500’s average for that same month — isolating Sanofi ADR’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, April has closed higher 80% of the time versus 70% across the last 10 years — the pattern is strengthening.
Figures are the typical (median) April return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The seasonal story is really one month's story — April. It has closed higher in 7 of 10 Aprils, a concentration the rest of the calendar can't touch.
A typical April brings +1.5%, a shade under the +2.6% average. Better still, that strength is the stock's own and not just a buoyant market — April has outpaced the S&P 500 by +1.0 points on average. Few peers keep such company in April — the typical stock clears it just 55% of the time.
April anchors a run, too: the March-through-June window has been the stock's reliable season. The weaker half of the year is plainer: February has been the soft spot — the weakest of 4 months that average a loss (−2.3%), and the edge isn't year-round — the stock has trailed the S&P 500 in October, July, and November. Its roughest month on record was a −16.1% August in 2022 — a reminder of how hard even a seasonal name can fall.
If anything it has sharpened recently — the last five Aprils run ahead of the earlier years.
For a stock this dependable in April, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on.
Short answers on the stock's best month (April), its worst (February), and whether it really trades seasonally.
Yes, to a moderate degree. Since 2016 its best month (April, +2.6%) has run well ahead of its worst (February, −2.3%) — the heatmap above shows how steady that gap has been year to year.
April has been the strongest, averaging +2.6% and closing higher in 7 of 10 years since 2016.
It's the weakest, averaging −2.3% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade